Yushen Qian

Yushen Qian

Auto-generated profile, based on publicly available information

Yushen Qian

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LPLeslie A. Parsels
Leslie A. Parsels
YQYushen Qian
Yushen Qian
DTDaria M. Tanska
Daria M. Tanska
MGMarisa Gross
Marisa Gross
LZLili Zhao
Lili Zhao
MMMeredith A. Morgan
Meredith A. Morgan
Purpose: Chk1 inhibitors, such as AZD7762, are in clinical development in combination with cytotoxic agents for the treatment of solid tumors, including pancreatic cancers. To maximize the likelihood of their clinical success, it is essential to optimize drug scheduling as well as pharmacodynamic biomarkers in preclinical models. Experimental Design: We tested multiple schedules of administration of gemcitabine and AZD7762 on the survival of pancreatic cancer cells. Potential pharmacodynamic biomarkers including pChk1, pChk2, pHistone H3, and caspase-3 were evaluated in vitro, followed by assessment of promising candidate biomarkers in vivo. We then went on to determine the contributions of PP2A and DNA damage to the mechanism(s) of induction of the identified biomarker, pS345 Chk1. Results: AZD7762 given during and after or after gemcitabine administration produced maximum chemosensitization. In vivo, AZD7762 significantly inhibited the growth of pancreatic tumor xenografts in response to gemcitabine. Of the biomarkers assessed, pS345 Chk1 was most consistently increased in response to gemcitabine and AZD7762 in tumors and normal tissues (hair follicles). pS345 Chk1 induction in response to gemcitabine and AZD7762 occurred in the presence of PP2A inhibition and in association with elevated γH2AX, suggesting that DNA damage is an underlying mechanism. Conclusions: AZD7762 sensitizes pancreatic cancer cells and tumors to gemcitabine in association with induction of pS345 Chk1. Together these data support the clinical investigation of AZD7762 with gemcitabine in pancreatic cancer under a dosing schedule in which gemcitabine is administered concurrent with or before AZD7762 and in conjunction with skin biopsies to measure pS345 Chk1. Clin Cancer Res; 17(11); 3706–15. ©2011 AACR.

1 October 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
YQYushen Qian
Yushen Qian
EPErqi L. Pollom
Erqi L. Pollom
CNChika Nwachukwu
Chika Nwachukwu
KSKira Seiger
Kira Seiger
RERie von Eyben
Rie von Eyben
EKElizabeth A. Kidd
Elizabeth A. Kidd